Florida Cancer Specialists Presents 32 Abstracts at 2026 ASCO Meeting
Event summary
- Florida Cancer Specialists & Research Institute (FCS) will present 32 abstracts and presentations at the 2026 ASCO Annual Meeting.
- Thirteen FCS physicians and leaders will showcase outcomes from early and late-phase clinical trials conducted at FCS Phase 1 Drug Development Units.
- Research highlights include innovative treatment strategies and cutting-edge targeted therapies for a wide range of cancers.
- FCS conducts over 180 active clinical trials annually, positioning it as a leader in oncology research.
The big picture
Florida Cancer Specialists' extensive research program underscores its role as a key player in advancing cancer care through clinical trials and precision oncology. The presentation of 32 abstracts at the 2026 ASCO Annual Meeting highlights FCS's commitment to innovative treatment strategies and targeted therapies, positioning it as a leader in the oncology research landscape. The collaboration with Sarah Cannon Research Institute and Paradigm Health further strengthens its ability to deliver cutting-edge care close to home.
What we're watching
- Research Impact
- How the outcomes of these clinical trials will influence future cancer treatment protocols and FDA approvals.
- Strategic Partnerships
- Whether FCS can sustain its leadership position through continued collaboration with SCRI and Paradigm Health.
- Therapeutic Breakthroughs
- The pace at which FCS's targeted therapies and precision oncology research translate into commercialized treatments.
Related topics